Cargando…

A211 INCIDENCE OF PRIMARY SCLEROSING CHOLANGITIS: A META-ANALYSIS OF POPULATION-BASED STUDIES

BACKGROUND: Primary sclerosing cholangitis (PSC) is a chronic liver disease associated with significant morbidity, mortality and healthcare utilization. Understanding the incidence of PSC is important in defining the burden of disease and planning for allocation of healthcare resources. AIMS: To con...

Descripción completa

Detalles Bibliográficos
Autores principales: Cooper, J, Markovinovic, A, Coward, S, Shaheen, A M, Swain, M, Panaccione, R, Ma, C, Novak, K L, Kaplan, G G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8859279/
http://dx.doi.org/10.1093/jcag/gwab049.210
_version_ 1784654421600239616
author Cooper, J
Markovinovic, A
Coward, S
Shaheen, A M
Swain, M
Panaccione, R
Ma, C
Novak, K L
Kaplan, G G
author_facet Cooper, J
Markovinovic, A
Coward, S
Shaheen, A M
Swain, M
Panaccione, R
Ma, C
Novak, K L
Kaplan, G G
author_sort Cooper, J
collection PubMed
description BACKGROUND: Primary sclerosing cholangitis (PSC) is a chronic liver disease associated with significant morbidity, mortality and healthcare utilization. Understanding the incidence of PSC is important in defining the burden of disease and planning for allocation of healthcare resources. AIMS: To conduct a systematic review and meta-analysis of population-based studies of the incidence of PSC and to assess temporal trends of incidence overtime. METHODS: Medline and Embase (from inception to May 10, 2021) were systematically searched to identify studies via the following inclusion criteria: 1) original articles, 2) population-based study of defined geographic area, 3) reported the incidence of PSC or provided data to calculate the incidence of PSC. Studies that assessed specific populations (e.g., pediatric-only, IBD-only) or reported less than 1 year of data were excluded. Abstracts and full texts were reviewed for inclusion and data was extracted independently in duplicate by two individuals (JC, AM). Meta-analyses were performed to calculate overall and country-specific incidence rates (per 100,000 persons) with 95% confidence intervals (CI). Meta-regression calculated the Average Annual Percentage Change (AAPC) of PSC incidence rates overtime. RESULTS: The initial search returned 3,958 abstracts. After duplicates were removed, abstracts (3,443) were screened, and full texts were reviewed (317), 17 studies met the criteria for inclusion and underwent data extraction. Meta-analysis included 6 studies with annual data contributing to the calculation of AAPC. Studies originated from 10 countries from North America, Europe, and Oceania; however, no population-based studies were published in Asia, Africa, or Latin America (Figure 1). Overall, the incidence rates of PSC was 0.82 per 100,000 (95% CI: 0.62, 1.02) (Figure 1). Incidence rates of PSC were significantly increasing overtime (AAPC: 4.56%; 95% CI: 0.45, 8.68). CONCLUSIONS: The incidence of PSC is low at 0.82 per 100,000 but has been significantly increasing over time. Future studies on the incidence of PSC should be directed at Asia, Africa of Latin America to assess the global epidemiology of PSC. [Image: see text] Figure 1: Pooled incidence rate estimates of PSC per 100,000 person-years at risk. FUNDING AGENCIES: None
format Online
Article
Text
id pubmed-8859279
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-88592792022-02-22 A211 INCIDENCE OF PRIMARY SCLEROSING CHOLANGITIS: A META-ANALYSIS OF POPULATION-BASED STUDIES Cooper, J Markovinovic, A Coward, S Shaheen, A M Swain, M Panaccione, R Ma, C Novak, K L Kaplan, G G J Can Assoc Gastroenterol Poster of Distinction BACKGROUND: Primary sclerosing cholangitis (PSC) is a chronic liver disease associated with significant morbidity, mortality and healthcare utilization. Understanding the incidence of PSC is important in defining the burden of disease and planning for allocation of healthcare resources. AIMS: To conduct a systematic review and meta-analysis of population-based studies of the incidence of PSC and to assess temporal trends of incidence overtime. METHODS: Medline and Embase (from inception to May 10, 2021) were systematically searched to identify studies via the following inclusion criteria: 1) original articles, 2) population-based study of defined geographic area, 3) reported the incidence of PSC or provided data to calculate the incidence of PSC. Studies that assessed specific populations (e.g., pediatric-only, IBD-only) or reported less than 1 year of data were excluded. Abstracts and full texts were reviewed for inclusion and data was extracted independently in duplicate by two individuals (JC, AM). Meta-analyses were performed to calculate overall and country-specific incidence rates (per 100,000 persons) with 95% confidence intervals (CI). Meta-regression calculated the Average Annual Percentage Change (AAPC) of PSC incidence rates overtime. RESULTS: The initial search returned 3,958 abstracts. After duplicates were removed, abstracts (3,443) were screened, and full texts were reviewed (317), 17 studies met the criteria for inclusion and underwent data extraction. Meta-analysis included 6 studies with annual data contributing to the calculation of AAPC. Studies originated from 10 countries from North America, Europe, and Oceania; however, no population-based studies were published in Asia, Africa, or Latin America (Figure 1). Overall, the incidence rates of PSC was 0.82 per 100,000 (95% CI: 0.62, 1.02) (Figure 1). Incidence rates of PSC were significantly increasing overtime (AAPC: 4.56%; 95% CI: 0.45, 8.68). CONCLUSIONS: The incidence of PSC is low at 0.82 per 100,000 but has been significantly increasing over time. Future studies on the incidence of PSC should be directed at Asia, Africa of Latin America to assess the global epidemiology of PSC. [Image: see text] Figure 1: Pooled incidence rate estimates of PSC per 100,000 person-years at risk. FUNDING AGENCIES: None Oxford University Press 2022-02-21 /pmc/articles/PMC8859279/ http://dx.doi.org/10.1093/jcag/gwab049.210 Text en ڣ The Author(s) 2022. Published by Oxford University Press on behalf of the Canadian Association of Gastroenterology. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Poster of Distinction
Cooper, J
Markovinovic, A
Coward, S
Shaheen, A M
Swain, M
Panaccione, R
Ma, C
Novak, K L
Kaplan, G G
A211 INCIDENCE OF PRIMARY SCLEROSING CHOLANGITIS: A META-ANALYSIS OF POPULATION-BASED STUDIES
title A211 INCIDENCE OF PRIMARY SCLEROSING CHOLANGITIS: A META-ANALYSIS OF POPULATION-BASED STUDIES
title_full A211 INCIDENCE OF PRIMARY SCLEROSING CHOLANGITIS: A META-ANALYSIS OF POPULATION-BASED STUDIES
title_fullStr A211 INCIDENCE OF PRIMARY SCLEROSING CHOLANGITIS: A META-ANALYSIS OF POPULATION-BASED STUDIES
title_full_unstemmed A211 INCIDENCE OF PRIMARY SCLEROSING CHOLANGITIS: A META-ANALYSIS OF POPULATION-BASED STUDIES
title_short A211 INCIDENCE OF PRIMARY SCLEROSING CHOLANGITIS: A META-ANALYSIS OF POPULATION-BASED STUDIES
title_sort a211 incidence of primary sclerosing cholangitis: a meta-analysis of population-based studies
topic Poster of Distinction
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8859279/
http://dx.doi.org/10.1093/jcag/gwab049.210
work_keys_str_mv AT cooperj a211incidenceofprimarysclerosingcholangitisametaanalysisofpopulationbasedstudies
AT markovinovica a211incidenceofprimarysclerosingcholangitisametaanalysisofpopulationbasedstudies
AT cowards a211incidenceofprimarysclerosingcholangitisametaanalysisofpopulationbasedstudies
AT shaheenam a211incidenceofprimarysclerosingcholangitisametaanalysisofpopulationbasedstudies
AT swainm a211incidenceofprimarysclerosingcholangitisametaanalysisofpopulationbasedstudies
AT panaccioner a211incidenceofprimarysclerosingcholangitisametaanalysisofpopulationbasedstudies
AT mac a211incidenceofprimarysclerosingcholangitisametaanalysisofpopulationbasedstudies
AT novakkl a211incidenceofprimarysclerosingcholangitisametaanalysisofpopulationbasedstudies
AT kaplangg a211incidenceofprimarysclerosingcholangitisametaanalysisofpopulationbasedstudies